AI Tokens
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Common Stock Valuation Ratios (Price Multiples)

Microsoft Excel

Current Valuation Ratios

Celgene Corp., current price multiples

Microsoft Excel
Celgene Corp. AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Selected Financial Data
Current share price (P) $108.03
No. shares of common stock outstanding 711,714,480
Growth rate (g) 38.99%
 
Earnings per share (EPS) $5.68
Next year expected EPS $7.90
Operating profit per share $7.29
Sales per share $21.45
Book value per share (BVPS) $8.66
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 19.00 120.56 32.27 18.29 44.06 62.20 24.42 24.46 19.86 21.92 20.73 37.41 34.79
Price to next year expected earnings 13.67 653.53 23.93 16.67 40.63 47.73 33.58 21.53 — 23.71 17.62 33.00 29.65
Price-earnings-growth (PEG) 0.49 — 0.93 1.87 5.21 2.05 — 1.80 — — 1.18 2.80 2.00
Price to operating profit (P/OP) 14.81 33.80 27.41 12.90 33.95 48.81 20.74 25.92 17.09 11.96 26.11 32.38 32.96
Price to sales (P/S) 5.04 8.33 7.08 2.68 6.48 19.70 7.19 6.96 5.58 2.72 6.51 5.63 11.46
Price to book value (P/BV) 12.48 — 28.74 6.99 3.03 48.38 9.15 8.04 6.89 1.97 2.99 4.70 7.37

Based on: 10-K (reporting date: 2018-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Celgene Corp., historical price multiples

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Price to earnings (P/E) 15.57 24.35 44.99 48.59 49.41
Price to operating profit (P/OP) 12.13 15.21 28.40 34.53 39.23
Price to sales (P/S) 4.13 5.52 8.04 8.50 13.06
Price to book value (P/BV) 10.22 10.34 13.63 13.15 15.14

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).


A comprehensive analysis of the valuation multiples from 2014 to 2018 reveals a systemic and significant contraction across all measured ratios. The consistent downward trajectory across price-to-earnings, price-to-operating profit, price-to-sales, and price-to-book value indicates a substantial devaluation of the equity relative to fundamental financial metrics over the five-year period.

Price to Earnings (P/E)
A significant contraction is observed in the P/E ratio, which declined from 49.41 in 2014 to 15.57 by 2018. The most pronounced reduction occurred between 2016 and 2018, suggesting a shift in market sentiment or a substantial increase in earnings that was not matched by a corresponding increase in share price.
Price to Operating Profit (P/OP)
The P/OP ratio followed a similar trajectory to the P/E ratio, decreasing from 39.23 in 2014 to 12.13 in 2018. This steady decline indicates that the market's valuation of the company's core operational profitability compressed significantly over the period.
Price to Sales (P/S)
A consistent downward trend is evident in the P/S ratio, which fell from 13.06 in 2014 to 4.13 in 2018. This suggests that the premium paid for each dollar of revenue generated by the company decreased substantially, reflecting a less optimistic outlook on revenue growth or a decline in the perceived quality of sales.
Price to Book Value (P/BV)
The P/BV ratio exhibited a general decline from 15.14 in 2014 to 10.22 in 2018. Although this ratio showed more stability than the earnings and sales multiples, the overall trend confirms a compression in the market value of the company relative to its net asset value.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Earnings (P/E)

Celgene Corp., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 702,164,345 752,175,608 777,966,471 781,664,535 800,590,656
Selected Financial Data (US$)
Net income (in millions) 4,046 2,940 1,999 1,602 2,000
Earnings per share (EPS)2 5.76 3.91 2.57 2.05 2.50
Share price1, 3 89.71 95.16 115.61 99.59 123.43
Valuation Ratio
P/E ratio4 15.57 24.35 44.99 48.59 49.41
Benchmarks
P/E Ratio, Competitors5
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Data adjusted for splits and stock dividends.

2 2018 Calculation
EPS = Net income ÷ No. shares of common stock outstanding
= 4,046,000,000 ÷ 702,164,345 = 5.76

3 Closing price as at the filing date of Celgene Corp. Annual Report.

4 2018 Calculation
P/E ratio = Share price ÷ EPS
= 89.71 ÷ 5.76 = 15.57

5 Click competitor name to see calculations.


An analysis of the financial metrics from 2014 to 2018 reveals a significant divergence between the growth in earnings and the market valuation of the stock. While profitability per share increased substantially over the period, the share price experienced a general decline, resulting in a sharp contraction of the price-to-earnings multiple.

Earnings Per Share (EPS) Performance
EPS exhibited a strong upward trajectory following a brief decline in 2015. From a low of 2.05 USD in 2015, earnings grew consistently to 5.76 USD by December 31, 2018. This represents a significant increase in bottom-line profitability over the five-year window.
Share Price Volatility
The share price demonstrated an overall downward trend characterized by periodic volatility. After reaching a peak of 123.43 USD in 2014, the price declined to 89.71 USD by the end of 2018, indicating a reduction in market capitalization despite the improvement in earnings.
Price-to-Earnings (P/E) Ratio Contraction
A consistent and accelerating decline in the P/E ratio is observed. The ratio began at 49.41 in 2014 and remained elevated through 2016. However, a sharp compression occurred in 2017 and 2018, with the ratio falling to 24.35 and 15.57, respectively. This trend indicates a substantial reduction in the premium investors were willing to pay for each dollar of earnings, suggesting a fundamental re-rating of the stock's valuation multiple.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Operating Profit (P/OP)

Celgene Corp., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 702,164,345 752,175,608 777,966,471 781,664,535 800,590,656
Selected Financial Data (US$)
Operating income (in millions) 5,191 4,707 3,167 2,255 2,519
Operating profit per share2 7.39 6.26 4.07 2.88 3.15
Share price1, 3 89.71 95.16 115.61 99.59 123.43
Valuation Ratio
P/OP ratio4 12.13 15.21 28.40 34.53 39.23
Benchmarks
P/OP Ratio, Competitors5
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Data adjusted for splits and stock dividends.

2 2018 Calculation
Operating profit per share = Operating income ÷ No. shares of common stock outstanding
= 5,191,000,000 ÷ 702,164,345 = 7.39

3 Closing price as at the filing date of Celgene Corp. Annual Report.

4 2018 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 89.71 ÷ 7.39 = 12.13

5 Click competitor name to see calculations.


A significant divergence is observed between operational performance and market valuation from 2014 to 2018. While the company achieved substantial growth in operating profitability per share, the market price for the stock experienced an overall decline, resulting in a sharp contraction of the price-to-operating profit (P/OP) multiple.

Share Price Movement
The share price followed a general downward trajectory, decreasing from 123.43 US$ in 2014 to 89.71 US$ in 2018. Although a brief recovery was noted in 2016 with a peak of 115.61 US$, the price failed to sustain those levels, ending the period lower than its 2014 starting point.
Operating Profit per Share Growth
Operating profit per share exhibited a strong and consistent upward trend. After a slight dip in 2015 to 2.88 US$, profitability grew rapidly, reaching 7.39 US$ by 2018. This indicates a marked improvement in operational efficiency and earnings generation over the five-year period.
P/OP Ratio Compression
The P/OP ratio declined precipitously from 39.23 in 2014 to 12.13 in 2018. This contraction was driven by the simultaneous occurrence of falling share prices and rising operating profits. The result is a valuation where the market paid significantly less for each unit of operating profit in 2018 than it did at the beginning of the analyzed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Sales (P/S)

Celgene Corp., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 702,164,345 752,175,608 777,966,471 781,664,535 800,590,656
Selected Financial Data (US$)
Net product sales (in millions) 15,265 12,973 11,185 9,161 7,564
Sales per share2 21.74 17.25 14.38 11.72 9.45
Share price1, 3 89.71 95.16 115.61 99.59 123.43
Valuation Ratio
P/S ratio4 4.13 5.52 8.04 8.50 13.06
Benchmarks
P/S Ratio, Competitors5
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Data adjusted for splits and stock dividends.

2 2018 Calculation
Sales per share = Net product sales ÷ No. shares of common stock outstanding
= 15,265,000,000 ÷ 702,164,345 = 21.74

3 Closing price as at the filing date of Celgene Corp. Annual Report.

4 2018 Calculation
P/S ratio = Share price ÷ Sales per share
= 89.71 ÷ 21.74 = 4.13

5 Click competitor name to see calculations.


Analysis of the five-year period from 2014 to 2018 reveals a significant divergence between revenue generation and market valuation. While sales per share grew consistently, the market multiple applied to those sales contracted sharply over the same interval.

Sales per Share Growth
A consistent upward trend is observed in sales per share, which increased from 9.45 US$ in 2014 to 21.74 US$ by December 31, 2018. This indicates a steady and substantial expansion in the company's ability to generate revenue on a per-share basis.
Share Price Volatility
The share price demonstrated an overall decline despite intermittent fluctuations. From a high of 123.43 US$ in 2014, the price decreased to 89.71 US$ by the end of 2018, reflecting a general downward pressure on the equity value.
Price-to-Sales (P/S) Ratio Compression
The P/S ratio experienced a continuous and steep contraction, falling from 13.06 in 2014 to 4.13 in 2018. This decline is the result of the simultaneous increase in sales per share and the general decrease in share price, signaling a significant reduction in the valuation premium the market assigned to the company's revenue.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Price to Book Value (P/BV)

Celgene Corp., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
No. shares of common stock outstanding1 702,164,345 752,175,608 777,966,471 781,664,535 800,590,656
Selected Financial Data (US$)
Stockholders’ equity (in millions) 6,161 6,921 6,599 5,919 6,525
Book value per share (BVPS)2 8.77 9.20 8.48 7.57 8.15
Share price1, 3 89.71 95.16 115.61 99.59 123.43
Valuation Ratio
P/BV ratio4 10.22 10.34 13.63 13.15 15.14
Benchmarks
P/BV Ratio, Competitors5
AbbVie Inc. — — — — —
Amgen Inc. — — — — —
Bristol-Myers Squibb Co. — — — — —
Danaher Corp. — — — — —
Eli Lilly & Co. — — — — —
Gilead Sciences Inc. — — — — —
Johnson & Johnson — — — — —
Merck & Co. Inc. — — — — —
Pfizer Inc. — — — — —
Regeneron Pharmaceuticals Inc. — — — — —
Thermo Fisher Scientific Inc. — — — — —
Vertex Pharmaceuticals Inc. — — — — —

Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).

1 Data adjusted for splits and stock dividends.

2 2018 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 6,161,000,000 ÷ 702,164,345 = 8.77

3 Closing price as at the filing date of Celgene Corp. Annual Report.

4 2018 Calculation
P/BV ratio = Share price ÷ BVPS
= 89.71 ÷ 8.77 = 10.22

5 Click competitor name to see calculations.


Between 2014 and 2018, a consistent compression in the Price to Book Value (P/BV) ratio is evident, reflecting a reduction in the market premium attributed to the company's net assets.

Price to Book Value Trend
The P/BV ratio declined from a peak of 15.14 in 2014 to 10.22 by the end of 2018. This represents a significant decrease in the multiple the market was willing to pay relative to the accounting value of the equity. While a minor recovery occurred in 2016, where the ratio rose to 13.63 from 13.15, the subsequent two years saw a more pronounced decline, with the ratio stabilizing near the 10x mark by 2018.
Share Price Influence
The primary driver of the P/BV contraction was the overall downward movement in the share price. The market price fell from 123.43 in 2014 to 89.71 in 2018. The volatility in the share price, including a temporary increase in 2016, directly correlated with the fluctuations observed in the valuation multiple.
Book Value Stability
Book Value per Share (BVPS) remained relatively stable with a modest upward trajectory for the majority of the analyzed period. After a decline to 7.57 in 2015, BVPS increased to a peak of 9.20 in 2017 before adjusting to 8.77 in 2018. Because the BVPS showed limited variance compared to the share price, the P/BV ratio remained highly sensitive to market price movements rather than changes in the company's underlying equity base.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?